Heike Irmgard Grabsch

List of Publications by Year
in descending order

106 papers	8,200 citations	116194 36 h-index	62345 84 g-index
115 all docs	115 docs citations	115 times ranked	9109 citing authors

#	ARTICLE	IF	CITATIONS
1	Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut, 2022, 71, 676-685.	6.1	21
2	Weakly supervised annotation–free cancer detection and prediction of genotype in routine histopathology. Journal of Pathology, 2022, 256, 50-60.	2.1	48
3	Deep learning identifies inflamed fat as a risk factor for lymph node metastasis in early colorectal cancer. Journal of Pathology, 2022, 256, 269-281.	2.1	39
4	Expression of proteins associated with the Warburg–effect and survival in colorectal cancer. Journal of Pathology: Clinical Research, 2022, 8, 169-180.	1.3	11
5	Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma. British Journal of Surgery, 2022, 109, 291-297.	0.1	4
6	Energy balance–related factors in childhood and adolescence and risk of colorectal cancer expressing different levels of proteins involved in the Warburg–effect. International Journal of Cancer, 2022, 150, 1812-1824.	2.3	9
7	Energy Balance–Related Factors and Risk of Colorectal Cancer Expressing Different Levels of Proteins Involved in the Warburg Effect. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 633-646.	1.1	6
8	Epidemiological, clinical and endoscopic characteristics of colorectal neuroendocrine neoplasms: a population-based study in the Netherlands. Endoscopy International Open, 2022, 10, E940-E951.	0.9	3
9	An Introduction to Deep Learning in Pathology. , 2022, , 137-151.		0
10	Artificial intelligence for detection of microsatellite instability in colorectal cancer—a multicentric analysis of a pre-screening tool for clinical application. ESMO Open, 2022, 7, 100400.	2.0	47
11	Data Set for Reporting Carcinoma of the Stomach in Gastrectomy. Archives of Pathology and Laboratory Medicine, 2022, 146, 1072-1083.	1.2	5
12	Swarm learning for decentralized artificial intelligence in cancer histopathology. Nature Medicine, 2022, 28, 1232-1239.	15.2	77
13	Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status. Journal of Cancer Research and Clinical Oncology, 2022, 148, 2723-2742.	1.2	3
14	Author response to: Increasing frequency of gene copy number aberrations is associated with immunosuppression and predicts poor prognosis in gastric adenocarcinoma. British Journal of Surgery, 2022, , .	0.1	0
15	Benchmarking weakly-supervised deep learning pipelines for whole slide classification in computational pathology. Medical Image Analysis, 2022, 79, 102474.	7.0	64
16	Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. Cancer Research, 2022, 82, 2538-2551.	0.4	7
17	Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials. European Journal of Cancer, 2022, 170, 140-148.	1.3	1
18	Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. Gut, 2021, 70, 1823-1832.	6.1	38

#	ARTICLE	IF	CITATIONS
19	Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. Journal of the National Cancer Institute, 2021, 113, 88-98.	3.0	15
20	Lymph node response to chemoradiotherapy in oesophageal cancer patients: relationship with radiotherapy fields. Esophagus, 2021, 18, 100-110.	1.0	1
21	Real-time lipid patterns to classify viable and necrotic liver tumors. Laboratory Investigation, 2021, 101, 381-395.	1.7	7
22	Deep learning detects genetic alterations in cancer histology generated by adversarial networks. Journal of Pathology, 2021, 254, 70-79.	2.1	31
23	Validation of the 'Inflammatory Bowel Disease—Distribution, Chronicity, Activity [IBD-DCA] Score' for Ulcerative Colitis and Crohn´s Disease. Journal of Crohn's and Colitis, 2021, 15, 1621-1630.	0.6	21
24	Validity and Reproducibility of Immunohistochemical Scoring by Trained Non-Pathologists on Tissue Microarrays. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1867-1874.	1.1	7
25	Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer, 2021, 153, 153-161.	1.3	8
26	Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes. Human Pathology, 2021, 116, 94-101.	1.1	9
27	Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 2021, 3, e654-e664.	5.9	69
28	Maximizing the diagnostic information from biopsies in chronic inflammatory bowel diseases: recommendations from the Erlangen International Consensus Conference on Inflammatory Bowel Diseases and presentation of the IBD-DCA score as a proposal for a new index for histologic activity assessment in ulcerative colitis and Crohn's disease. Virchows Archiv Fur Pathologische Anatomie Und Fur Klinische Medizin, 2021, 478, 581-594.	1.4	26
29	Predicting Mutational Status of Driver and Suppressor Genes Directly from Histopathology With Deep Learning: A Systematic Study Across 23 Solid Tumor Types. Frontiers in Genetics, 2021, 12, 806386.	1.1	14
30	Deep learning for the detection of microsatellite instability from histology images in colorectal cancer: A systematic literature review. ImmunoInformatics, 2021, 3-4, 100008.	1.2	21
31	Interobserver, intraobserver, and interlaboratory variability in reporting pT4a colon cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 219-230.	1.4	12
32	Microscopic intramural extension of rectal cancer after neoadjuvant chemoradiation: A meta-analysis based on individual patient data. Radiotherapy and Oncology, 2020, 144, 37-45.	0.3	4
33	Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. European Journal of Cancer, 2020, 124, 67-76.	1.3	16
34	Large negative lymph nodes – a surrogate for immune activation in rectal cancer patients?. Pathology Research and Practice, 2020, 216, 153106.	1.0	4
35	Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02,) Tj ETQq1 1 0.784314 rgBT /Overlo		
36	Pan-cancer image-based detection of clinically actionable genetic alterations. Nature Cancer, 2020, 1, 789-799.	5.7	343

#	Article	IF	Citations
37	Gastric cancer. Lancet, The, 2020, 396, 635-648.	6.3	2,084
38	Mucin expression in gastric- and gastro-oesophageal signet-ring cell cancer: results from a comprehensive literature review and a large cohort study of Caucasian and Asian gastric cancer. Gastric Cancer, 2020, 23, 765-779.	2.7	13
39	Efficacy of Dose-Escalated Chemoradiation on Complete Tumor Response in Patients with Locally Advanced Rectal Cancer (RECTAL-BOOST): A Phase 2 Randomized Controlled Trial. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1008-1018.	0.4	51
40	Clinical-Grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. Gastroenterology, 2020, 159, 1406-1416.e11.	0.6	209
41	Hypothesisâ€free deep survival learning applied to the tumour microenvironment in gastric cancer. Journal of Pathology: Clinical Research, 2020, 6, 273-282.	1.3	21
42	A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta OncolÃ³gica, 2020, 59, 895-903.	0.8	10
43	Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer. Journal of Clinical Investigation, 2020, 130, 3005-3020.	3.9	12
44	Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.. Journal of Clinical Oncology, 2020, 38, 373-373.	0.8	3
45	Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction. British Journal of Surgery, 2019, 106, 1204-1215.	0.1	6
46	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 2019, 37, 3392-3400.	0.8	293
47	Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer. Nature Medicine, 2019, 25, 1054-1056.	15.2	773
48	KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study. Gastric Cancer, 2019, 22, 1193-1203.	2.7	16
49	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. European Journal of Cancer, 2019, 112, 1-8.	1.3	23
50	Tumourâ€specific and organâ€specific protein synthesis rates in patients with pancreatic cancer. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 549-556.	2.9	15
51	Immunophenotypes of pancreatic ductal adenocarcinoma: Metaâ€analysis of transcriptional subtypes. International Journal of Cancer, 2019, 145, 1125-1137.	2.3	30
52	Comprehensive biomarker analyses identifies *HER2, EGFR, MET* RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. Journal of Cancer, 2019, 10, 5130-5138.	1.2	1
53	DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal of Cancer, 2019, 123, 48-57.	1.3	5
54	Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer, 2019, 22, 1-9.	2.7	114

#	ARTICLE	IF	CITATIONS
55	Response assessment after (chemo)radiotherapy for rectal cancer: Why are we missing complete responses with MRI and endoscopy?. European Journal of Surgical Oncology, 2019, 45, 1011-1017.	0.5	42
56	Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial.. Journal of Clinical Oncology, 2019, 37, 4006-4006.	0.8	49
57	Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC) Tj ETQq1 bQ8784314 rgBT /C		
58	DNA methylation signature predictive of benefit from neoadjuvant chemotherapy in esophageal adenocarcinoma: Results from the MRC OEO2 phase III trial.. Journal of Clinical Oncology, 2019, 37, 43-43.	0.8	1
59	MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).. Journal of Clinical Oncology, 2019, 37, 66-66.	0.8	17
60	Trends in treatment and overall survival among patients with proximal esophageal cancer. World Journal of Gastroenterology, 2019, 25, 6835-6846.	1.4	13
61	Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy â€" results from the <scp>MRC OE</scp>02 oesophageal cancer trial. Histopathology, 2018, 72, 1180-1188.	1.6	31
62	Prognostic DNA methylation markers for sporadic colorectal cancer: a systematic review. Clinical Epigenetics, 2018, 10, 35.	1.8	38
63	Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. European Journal of Cancer, 2018, 94, 104-114.	1.3	50
64	Frequent Coamplification of Receptor Tyrosine Kinase and Downstream Signaling Genes in Japanese Primary Gastric Cancer and Conversion in Matched Lymph Node Metastasis. Annals of Surgery, 2018, 267, 114-121.	2.1	15
65	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer, 2018, 18, 877.	1.1	115
66	Identification of a highâ€risk subtype of intestinalâ€type Japanese gastric cancer by quantitative measurement of the luminal tumor proportion. Cancer Medicine, 2018, 7, 4914-4923.	1.3	25
67	NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. European Journal of Cancer, 2017, 74, 38-46.	1.3	37
68	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2â€"3 trial. Lancet Oncology, The, 2017, 18, 357-370.	5.1	244
69	Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2017, 18, 1249-1260.	5.1	187
70	Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives. European Journal of Cancer, 2016, 59, 160-170.	1.3	78
71	Cervical esophageal cancer: a gap in cancer knowledge. Annals of Oncology, 2016, 27, 1664-1674.	0.6	75
72	Histopathological, Molecular, and Genetic Profile of Hereditary Diffuse Gastric Cancer: Current Knowledge and Challenges for the Future. Advances in Experimental Medicine and Biology, 2016, 908, 371-391.	0.8	47

#	Article	IF	Citations
73	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. Journal of Clinical Oncology, 2016, 34, 2721-2727.	0.8	214
74	The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors. Gastric Cancer, 2016, 19, 479-489.	2.7	22
75	Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer, 2016, 19, 553-560.	2.7	48
76	EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancer—INNOVATION trial.. Journal of Clinical Oncology, 2016, 34, TPS4133-TPS4133.	0.8	2
77	NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 3-3.	0.8	1
78	Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Oncotarget, 2016, 7, 77565-77575.	0.8	12
79	Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A. Oncotarget, 2016, 7, 6693-6710.	0.8	12
80	Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma. Oncotarget, 2016, 7, 44084-44095.	0.8	10
81	Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer, 2015, 15, 762.	1.1	38
82	Endoscopic biopsies from gastrointestinal carcinomas and their suitability for molecular analysis: a review of the literature and recommendations for clinical practice and research. Histopathology, 2015, 67, 147-157.	1.6	6
83	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut, 2015, 64, 1721-1731.	6.1	197
84	Technical Reproducibility of Single-Nucleotide and Size-Based DNA Biomarker Assessment Using DNA Extracted from Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2015, 17, 242-250.	1.2	8
85	RandomSpot: A web-based tool for systematic random sampling of virtual slides. Journal of Pathology Informatics, 2015, 6, 8.	0.8	15
86	NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer, 2015, 15, 48.	1.1	29
87	Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). British Journal of Cancer, 2015, 113, 716-721.	2.9	23
88	Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).. Journal of Clinical Oncology, 2015, 33, 4002-4002.	0.8	59
89	Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas. British Journal of Cancer, 2014, 110, 1525-1534.	2.9	56
90	FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. British Journal of Cancer, 2014, 110, 967-975.	2.9	154

#	Article	IF	Citations
91	Toxicity, surgical complications, and short-term mortality in a randomized trial of neoadjuvant cisplatin/5FU versus epirubicin/cisplatin and capecitabine prior to resection of lower esophageal/gastroesophageal junction (GOJ) adenocarcinoma (MRC OEO5, ISRCTN01852072, CRUK) Tj ETQq1 1 0.784314 rgBT /Over	0.8	4
92	NeoSCOPE: A phase II randomized comparison of neoadjuvant oxaliplatin/capecitabine versus carboplatin/paclitaxel-based chemoradiation in operable esophageal cancer.. Journal of Clinical Oncology, 2014, 32, TPS4144-TPS4144.	0.8	1
93	The relationship between tumor cell density in the pretreatment biopsy and survival after chemotherapy in OE02 trial esophageal cancer patients.. Journal of Clinical Oncology, 2014, 32, 49-49.	0.8	3
94	Prognostic and predictive value of tumor-infiltrating immune cells in Japanese patients with stage II/III gastric cancer.. Journal of Clinical Oncology, 2014, 32, 46-46.	0.8	1
95	Coamplification of receptor tyrosine kinases and downstream targets in Japanese gastric cancers.. Journal of Clinical Oncology, 2014, 32, 41-41.	0.8	0
96	The survival difference between gastric cancer patients from the United Kingdom and Japan after using weighted propensity score for adjustment of differing background factors.. Journal of Clinical Oncology, 2014, 32, 4055-4055.	0.8	0
97	Gastric Cancer Pathology and Underlying Molecular Mechanisms. Digestive Surgery, 2013, 30, 150-158.	0.6	79
98	KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study. British Journal of Cancer, 2013, 108, 1495-1501.	2.9	76
99	Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut, 2013, 62, 1100-1111.	6.1	139
100	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut, 2012, 61, 673-684.	6.1	562
101	Intrinsic Subtypes of Gastric Cancer, Based on Gene Expression Pattern, Predict Survival and Respond Differently to Chemotherapy. Gastroenterology, 2011, 141, 476-485.e11.	0.6	304
102	HER2 Expression in Gastric Cancer: Rare, Heterogeneous and of No Prognostic Value – Conclusions from 924 Cases of Two Independent Series. Analytical Cellular Pathology, 2010, 32, 57-65.	0.7	64
103	HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cellular Oncology, 2010, 32, 57-65.	1.9	140
104	Expression of DNA Double-Strand Break Repair Proteins ATM and BRCA1 Predicts Survival in Colorectal Cancer. Clinical Cancer Research, 2006, 12, 1494-1500.	3.2	71
105	Expression of BUB1 protein in gastric cancer correlates with the histological subtype, but not with DNA ploidy or microsatellite instability. Journal of Pathology, 2004, 202, 208-214.	2.1	31
106	Association between mutational subgroups, Warburg subtypes, and survival in patients with colorectal cancer. Cancer Medicine, 0, , .	1.3	4